v3.26.3
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Revenue:        
Total revenue $ 151,754 $ 131,872 $ 441,146 $ 376,509
Cost of revenue:        
Intangible asset amortization - cost of revenue 3,265 2,707 8,713 7,959
Total cost of revenue 44,650 40,590 124,334 115,950
Gross profit 107,104 91,282 316,812 260,559
Operating expenses:        
Research and development 32,159 15,981 88,699 49,965
Selling and marketing 28,652 24,455 84,071 74,225
General and administrative 29,302 27,278 80,425 93,417
Impairment of assets 0 0 0 20,505
Total operating expenses 90,535 68,336 254,617 239,977
Income from operations 16,569 22,946 62,195 20,582
Other income (loss), net 4,553 (4,057) 15,424 6,985
Income before income taxes 21,122 18,889 77,619 27,567
Income tax provision (benefit) (10,381) (248) (8,081) 2,363
Net income $ 31,503 $ 19,137 $ 85,700 $ 25,204
Earnings per share:        
Basic (in USD per share) $ 0.39 $ 0.24 $ 1.07 $ 0.32
Diluted (in USD per share) $ 0.38 $ 0.24 $ 1.04 $ 0.32
Shares used to compute earnings per common share:        
Basic (in shares) 80,500,406 78,725,139 80,006,663 78,384,184
Diluted (in shares) 82,783,915 79,691,703 82,204,307 79,946,386
Testing revenue        
Revenue:        
Total revenue $ 146,419 $ 127,756 $ 427,171 $ 357,328
Cost of revenue:        
Cost of revenue 38,477 33,777 108,092 94,444
Product revenue        
Revenue:        
Total revenue 4,626 3,301 12,163 10,479
Cost of revenue:        
Cost of revenue 2,766 3,015 7,172 6,186
Biopharmaceutical and other revenue        
Revenue:        
Total revenue 709 815 1,812 8,702
Cost of revenue:        
Cost of revenue 142 1,091 357 7,361
Intangible asset amortization - operating expenses        
Operating expenses:        
Intangible asset amortization - operating expenses $ 422 $ 622 $ 1,422 $ 1,865